Bonannione A

Bonannione A

SCHEMBL140804

CC(C)=CCC/C(C)=C/Cc1c(O)cc2c(c1O)C(=O)CC(c1ccc(O)cc1)O2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 4/20 1.00
PTGS2 P35354 4/20 1.00
TP53 P04637 1/20 1.00
MDM2 Q00987 1/20 1.00
ELANE P08246 6/20 0.84
ALOX5 P09917 3/20 0.84
CACNA1H O95180 3/20 0.83
CACNA1G O43497 1/20 0.83
ESR1 P03372 1/20 0.83
MAPT P10636 1/20 0.83
MAPK1 P28482 1/20 0.83
KMT2A Q03164 1/20 0.83
ATM Q13315 1/20 0.83
NPSR1 Q6W5P4 1/20 0.83
ABCG2 Q9UNQ0 1/20 0.76
PTPN1 P18031 1/20 0.67
PDE4D Q08499 1/20 0.66
PDCD1 Q15116 1/20 0.66
CD274 Q9NZQ7 1/20 0.66
PLA2G1B P04054 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bonannione A SCHEMBL16105830 1.00 ACHE (1.00) ACHEPTGS2TP53MDM2ELANE
Bonannione A SCHEMBL3231728 1.00 ACHE (1.00) ACHEPTGS2TP53MDM2ELANE
Bonannione A SCHEMBL29904527 1.00 ACHE (1.00) ACHEPTGS2TP53MDM2ELANE
Bonannione A SCHEMBL12780391 1.00 ACHE (1.00) ACHEPTGS2TP53MDM2ELANE
SCHEMBL18061372 0.94 ACHE (0.88) ACHEPTGS2TP53MDM2ELANE
SCHEMBL7794615 0.94 ACHE (0.88) ACHEPTGS2TP53MDM2ELANE
SCHEMBL4254357 0.93 ACHE (0.86) ACHEPTGS2TP53MDM2ELANE
Nymphaeol A SCHEMBL7795014 0.92 ELANE (1.00) ACHEPTGS2TP53MDM2ELANE
Nymphaeol A SCHEMBL16105856 0.92 ELANE (1.00) ACHEPTGS2TP53MDM2ELANE
Nymphaeol A SCHEMBL909992 0.92 ELANE (1.00) ACHEPTGS2TP53MDM2ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051551-A1 IMPROVED POLYMER COMPOSITES WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2025-02-13 US claimed
WO-2023193244-A1 SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM 北京睿创康泰医药研究院有限公司 2023-10-12 WO claimed
EP-4216920-A1 ORAL CARE COMPOSITIONS COMPRISING PRENYLATED FLAVONOIDS The Procter & Gamble Company (US) 2023-08-02 EP claimed
WO-2022067143-A1 ORAL CARE COMPOSITIONS COMPRISING PRENYLATED FLAVONOIDS THE PROCTER & GAMBLE COMPANY (US) 2022-03-31 WO claimed
US-20220096364-A1 Oral Care Compositions Comprising Prenylated Flavonoid THE PROCTER & GAMBLE COMPANY 2022-03-31 US claimed
US-20190046469-A1 COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE KUHRTS ERIC HAUSER (US) 2019-02-14 US claimed
US-20150209307-A1 COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE KUHRTS ERIC HAUSER (US) 2015-07-30 US claimed
WO-2014025989-A1 COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE KUHRTS ERIC HAUSER (US) 2014-02-13 WO claimed
US-20140045904-A1 NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE EFFECT KUHRTS ERIC HAUSER (US) 2014-02-13 US claimed
WO-2012051107-A2 NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE-EFFECT KUHRTS ERIC HAUSER (US) 2012-04-19 WO claimed
US-20090209654-A1 Prenylflavonoid Formulations BIOACTIVES, INC. 2009-08-20 US claimed
WO-2008095189-A1 METHODS AND COMPOSITIONS FOR TREATING DYSLIPIDAEMIA BIOACTIVES, INC. (US) 2008-08-07 WO claimed
WO-2008089137-A1 HOPS EXTRACTION METHODS AND MIXTURES BIOACTIVES, INC. (US) 2008-07-24 WO claimed
EP-1909584-A2 PRENYLFLAVONOID FORMULATIONS Bioactives, Inc. (US) 2008-04-16 EP claimed
US-20070218155-A1 Methods and compositions for treating dyslipidaemia BIOACTIVES, INC. 2007-09-20 US claimed
WO-2007016578-A2 PRENYLFLAVONOID FORMULATIONS BIOACTIVES, INC. (US) 2007-02-08 WO claimed
US-20050019438-A1 Hop extracts and use thereof in the production of a medicament having estrogenic properties BOURGES-SEVENIER CEDRIC (FR) 2005-01-27 US claimed
EP-1381379-A1 HOP EXTRACTS AND USE THEREOF IN THE PRODUCTION OF A MEDICAMENT HAVING ESTROGENIC PROPERTIES BERKEM (FR) 2004-01-21 EP claimed
WO-2002085393-A1 HOP EXTRACTS AND USE THEREOF IN THE PRODUCTION OF A MEDICAMENT HAVING ESTROGENIC PROPERTIES BERKEM (FR) 2002-10-31 WO claimed
WO-2001003687-A2 METHOD AND COMPOSITIONS FOR INHIBITING BIOSYNTHESIS OR BIOACTIVITY OF ENDOGENOUS STEROID SEX HORMONES IN HUMANS CEDARS-SINAI MEDICAL CENTER (US) 2001-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150209307-A1 COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE CUTA, PSEN2, PNN ACHE 808/4885PTGS2 2094/4885TP53 1146/4885
US-20190046469-A1 COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE CUTA, PSEN2, PNN ACHE 808/4885PTGS2 2094/4885TP53 1146/4885
US-20220096364-A1 Oral Care Compositions Comprising Prenylated Flavonoid PROC, F9, SP1 ACHE 309/4885PTGS2 4259/4885TP53 2293/4885
US-20140045904-A1 NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE EFFECT NAPRT, NISCH, NAMPT ACHE 1104/4885PTGS2 1870/4885TP53 4333/4885
US-20090209654-A1 Prenylflavonoid Formulations TP53, CYP46A1, HPGD ACHE 4372/4885PTGS2 311/4885TP53 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.